BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines tEVIMBRA — Global Revenue Growth YoY (%) (%)
Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases
Latest, Q2 2026
18.1%
Period ended Jun 30, 2026
Change on a year earlier
-4.1 pts
22.2% in Q2 2025
History
19 quarters
Since Q3 2021
Sources
19
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TEVIMBRA — Global Revenue Growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 18.1% | -4.1 pts | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 20.5% | +2.7 pts | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 18.0% | -2.0 pts | Form 8-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 16.7% | +3.9 pts | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 22.2% | +16.3 pts | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 17.8% | -8.6 pts | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 20.0% | – | Form 8-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 30, 2024 | 12.8% | +0.2 pts | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 5.9% | -36.6 pts | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 26.4% | -4.6 pts | Form 10-Q (filed 2024-05-08) ↗ |
| Q3 2023 | Sep 30, 2023 | 12.6% | -53.9 pts | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 42.5% | +2.4 pts | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 31.0% | -48.0 pts | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 88.0% | +102.0 pts | Form 8-K (filed 2023-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 66.5% | +12.5 pts | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 40.1% | – | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 79.0% | – | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2021 | Dec 31, 2021 | -14.0% | – | Form 8-K (filed 2022-02-25) ↗ |
| Q3 2021 | Sep 30, 2021 | 54.0% | – | Form 10-Q (filed 2021-11-04) ↗ |
Cite this data
StockData. (2026). BeOne Medicines TEVIMBRA — Global Revenue Growth YoY (%) (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_tevimbra_ww_yoy
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.